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Dietary conjugated linoleic acid reduces PGE2 release and
interstitial injury in rat polycystic kidney disease.
Background. Conjugated linoleic acid (CLA) describes po-
sitional isomers of linoleic acid (LA). Experimental health
benefits of CLA include amelioration of malignancy and in-
flammatory disease and reduction of adiposity. The Han:
SPRD-cy rat model of polycystic kidney disease (PKD) fea-
tures prominent renal interstitial inflammation and fibrosis that
is amenable to dietary modification. We studied CLA supple-
mentation in the modification of inflammatory outcomes in the
Han:SPRD-cy rat.
Methods. Male offspring of Han:SPRD-cy heterozygotes
were fed diets, using corn oil or corn oil with a CLA enriched oil
(1% of diet by weight as CLA). After 8 weeks, measurements
included renal function and morphometry, ex vivo release of
renal prostaglandin E2 (PGE2), and renal and hepatic tissue
fatty acid profiles.
Results. Urine creatinine was significantly higher in PKD
animals fed CLA (P  0.004), but differences in serum creati-
nine and creatinine clearance did not quite reach significance
in PKD animals. CLA feeding reduced interstitial inflammation
(P  0.001), fibrosis (P  0.03), and renal PGE2 release (P 
0.02). Cystic change and oxidized low-density lipoprotein
(LDL) staining did not change significantly. CLA feeding pro-
duced increased renal and hepatic CLA isomers. Hepatic, but
not renal, LA proportion was reduced on the CLA diet. The
renal proportion of the PGE2 precursor, arachidonic acid (AA),
was not changed by diet, but hepatic AA proportion increased
significantly with CLA feeding (P  0.009).
Conclusion. CLA reduces renal production of PGE2, with-
out reduced availability of the precursor fatty acid, AA. Short-
term feeding of CLA to Han:SPRD-cy rats also has significant
renal anti-inflammatory and antifibrotic effects. As inflamma-
tion and fibrosis are important components of the progression
of chronic renal injury, CLA may be a useful agent in dietary
amelioration of renal disease.
Key words: rat, polyunsaturated fatty acids, conjugated linoleic acid,
polycystic kidneys, interstitial nephritis.
Received for publication December 9, 2002
and in revised form February 14, 2003, and April 23, 2003
Accepted for publication May 23, 2003
 2003 by the International Society of Nephrology
1214
Modification of renal injury by specific dietary change
is a powerful tool both to provide insight into mecha-
nisms of renal disease and to develop new treatment
and prevention strategies. The Han:SPRD-cy model of
polycystic kidney disease (PKD), characterized by au-
tosomal-dominant inheritance with marked sexual di-
morphism in expression, has proved an excellent system
in which to explore the modification of chronic renal
injury, including injury by dietary means. Epithelial pro-
liferation and progressive dilatation of nephrons, marked
interstitial inflammation, and fibrosis characterize the dis-
ease [1]. Oxidant injury has been implicated in its patho-
genesis [2]. It can be ameliorated with methylpredniso-
lone [3], angiotensin blockade or angiotensin-converting
enzyme (ACE) inhibition [4, 5], and lovastatin [6]. Ame-
lioration occurs with dietary soy protein substitution
[7, 8], protein restriction [9], flaxseed [10, 11], and citrate
supplementation [12]. A pure animal protein-based diet
is associated with more rapid disease progression than
that seen with mixed vegetable and animal protein-based
rat chows [8, 10].
The effects of feeding flaxseed and soy [8, 10] were
associated with alteration of renal and hepatic polyunsat-
urated fatty acid (PUFA) content. The soy diet reduced
conversion of linoleic acid (LA) to the series 2 prostanoid
precursor, arachidonic acid (AA). The flaxseed diet ele-
vated 3 fatty acids. The extent of injury can also be
influenced by the total amount of fat in the diet, and
this, in turn, can be modified by altering the composition
of the fat [13]. Fish oil, a rich source of 3 fatty acids is
effective in reducing the negative effect of a high fat diet
[14]. Thus, the quality of the dietary fat and the response
of fatty acid metabolism to diet (i.e., soy protein or fat)
are capable of reducing severity of PKD. Whether dietary
incorporation of specific fatty acids linked to reducing
inflammation could ameliorate PKD has not been tested.
Conjugated linoleic acid (CLA) refers to a group of
positional and geometric isomers of LA produced by
bacterial action in the gastrointestinal tract of ruminants
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[15, 16]. CLA is a significant dietary component in hu-
mans on hunter-gatherer or primitive agrarian diets con-
taining the meat or milk of free-ranging ruminants, but
exposure is much lower in modern urban diets [17]. CLA
is absorbed well in a number of species and becomes
widely distributed in the body, although Kramer et al
[18] have found that tissue content of individual isomers
varies quite significantly. The isomers may compete with
LA at the level of desaturases and elongases, thus influ-
encing AA [19]. CLA reduces the expression of the gene
for stearoyl-CoA reductase, the initial 9-desaturase step
in the formation of monoenoic fatty acids [20].6-desatur-
ase inhibition by CLA has been reported in a transfected
yeast system [21], and by the t10, c12 isomer specifically
in human hepatoma cells [22]. Although found to have
benefits in the areas of carbohydrate metabolism, choles-
terol metabolism, and atherosclerosis [23], the major
health-related interest in CLA has been as an anticarci-
nogen [16]. CLA has been shown to have a dose-depen-
dent effect on tumor development or growth in skin,
prostate, mammary, and colonic tumors. CLA produces
tissue specific alteration in production of eicosanoids
[24, 25], and decreases release of AA or prostaglandin
E2 (PGE2) in different tissue types or cell lines [26–28].
CLA has been associated with improved outcome in
experimental porcine colitis [29], and is capable of ex-
erting an anti-inflammatory effect without compromising
resistance to infection [30]. CLA enhances lymphocyte
proliferative responses to phytohemagglutinin, but not
to lipopolysaccharide (LPS) or concanavalin A [31], im-
plying a positive or negative immunomodulatory role
under differing circumstances. Most CLA preparations
are a mixture of isomers, with the precise mix a function
of the both the substrate oil and the manufacturing pro-
cess [32]. Proportions of CLA are low in adult patients
with chronic renal failure managed without dialysis, but
increase in dialysis patients [33]. It is likely that changes
in dietary intake, with severe restriction of dairy products
mandated to maintain serum phosphate in an acceptable
range, are a major factor.
As CLA feeding has been associated with an anti-
inflammatory and antiproliferative responses, and has
been shown to affect fatty acid metabolism in a manner
consistent with other interventions in our previous stud-
ies in the Han:SPRD-cy rat, we conducted a study to
test the hypothesis that CLA would ameliorate the pro-
gression of chronic renal injury in this model. We further
hypothesized that CLA would reduce the renal produc-
tion of 6 series prostanoids, as represented by PGE2.
METHODS
Animals
All animal procedures and care were examined by the
University of Manitoba Committee on Animal Use and




Control linoleic acid (CLA)
(7% corn oil enriched corn oil
by weight) by weight]
16:0 10.6 9.4
18:0 2.7 2.0
18:1 c9 28.6 26.9
18:2 c9, c12 linoleic acid (LA) 56.3 48.1
18:2 c9, t11 (CLA) 0.0 5.2
18:2 t10, c12 (CLA) 0.0 0.3
18:2 (other CLA isomers) 0.0 4.0
18:3 -linoleic acid (ALA) 1.1 0.6
20:0 0.4 0.3
20:1 0 2.6
6:3 ratio 51.2 80.2
Figures except ratios are percent total lipid. Fatty acids other than CLA
isomers present at less than 1% of total lipid in both diets are not reported.
were within the guidelines of the Canadian Council on
Animal Care. Surviving male offspring of known Han:
SPRD-cy heterozygotes from our own breeding colony
were randomly assigned to treatment or control groups
at weaning at 3 weeks of age. Males only, two thirds of
which would be heterozygous, as homozygotes do not
survive beyond weaning, were used due to the more
rapid progress of this disease in male animals. Animals
were killed after 8 weeks on the diet and kidney and
liver tissue and serum collected for analysis. A fasting
6-hour urine collection was collected for creatinine clear-
ance using metabolic cages on the day prior to tissue
harvest. Diets were based on the AIN 93 formula using
casein as the protein source and 7% corn oil or 1.67%
CLA-enriched oil, which was a gift from Bioriginal, Sas-
katoon, Canada,  5.33% corn oil. This combination
aimed to produce 1% of diet by weight as CLA based
upon the manufacturer’s analysis, comparable to other
dietary studies in rodents [31, 34–36], although a subse-
quent analysis in our laboratory gave a concentration of
0.67% of diet as CLA isomers detectable on our system.
The composition of the diets was identical for nonlipid
components. The results of our analysis of the fatty acid
composition of the diets are shown in Table 1. Cages
containing one to three animals fed corn oil diet were
paired to cages of animals on CLA diet, with corn oil
diet intake limited to the amount consumed by the paired
CLA diet cage the previous day.
Histology and immunohistochemistry
Tissue from the left kidney was processed using our
previously described methods [7, 8, 10] for histologic and
immunohistochemical analysis. These studies included
hematoxylin and eosin, aniline blue staining for fibrosis,
and macrophages (MAB1435) (Chemicon International,
Temecula, CA, USA). Oxidized low-density lipoprotein
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(ox-LDL) staining was used as a marker of oxidant injury
[37], using a polyclonal antibody (AB3230) (Chemicon
International). Animals were classified as affected by
one of two experienced observers (N.B.C., M.R.O.),
blinded to dietary intervention on the basis of the charac-
teristic cystic and inflammatory pathology of this disease.
Image analysis
Image analysis procedures were performed with a sys-
tem consisting of a Spot Junior CCD camera mounted
on an Olympus BX60 microscope. The captured images
from random stage movement through the sections were
subsequently analyzed using Image Pro version 4.5 Pack-
age (Media Cybernetics, Silver Spring, MD, USA). The
observer was blinded to dietary treatment, although dis-
ease status was obvious upon microscopic examination.
Raw analysis data were processed as previously de-
scribed [4, 7–10] to give objective measures of cystic
change, fibrosis, interstitial macrophage infiltration and
extent of ox-LDL staining. Measurements of fibrosis and
cellular markers were corrected to solid tissue areas of
sections so that the presence of empty cystic areas on
the section did not lead to an underestimate of these
parameters.
Chemistry
Biochemical measurements were performed by an ob-
server blinded to disease and dietary status (E.N.). Se-
rum and urine creatinine, serum triglyceride, and serum
cholesterol were determined by spectrophotometric
methods using Sigma kits (Sigma Chemical Co., St. Louis,
MO, USA). Creatinine clearance was corrected to body
weight.
Gas chromatography
Lipids were extracted for gas chromatography (GC)
analysis using a modified Folch extraction procedure, as
we have previously described [8, 10, 38]. Prior to analysis,
samples were redissolved in 1 mL of dry toluene, mixed
with 2.0 mL of 0.5 M sodium methoxide and heated to
50C for 10 minutes, then mixed with 0.1 mL of glacial
acetic acid, 5 mL of distilled H2O, and 5 mL of hexane.
After vortexing, the mixture was centrifuged at 2500g
for 10 minutes and the hexane fraction removed. Fresh
hexane is added to the remaining solution and the previ-
ous steps repeated. The hexane fractions were dried un-
der anhydrous sodium sulfate, evaporated under nitro-
gen, and the lipid esters redissolved in 1 mL hexane. GC
was performed on a Varian Chrompack 3800 instrument,
using a Zebron ZB Wax 30 m column (Phenomenex,
Torrance, CA, USA). Specific CLA isomers were able
to be identified where standards were available. Total
6:3 ratio was calculated from the sum of proportions
of LA (18:2 c9,c12), -linolenic acid (GLA) (20:3 6),
and AA, divided by the sum of -linolenic acid (ALA)
(20:3 3), eicosapentaenoic acid (EPA), and docosahex-
aenoic acid (DHA). The ratios of palmitic acid (PT)
(16:0) to palmitoleic acid (PO) (16:1), and stearic acid
(ST) (18:0) to oleic acid (OL) (18:1) were calculated
as measure of -9 desaturase activity and LA:AA was
calculated as a measure of -6 desaturase activity.
PGE2 measurement
Approximately 250 mg of the left kidney was weighed
and homogenized immediately upon removal from the
animal in 10 mL of Hank’s balanced salt solution. The
homogenate was incubated at 37C for 1 hour, at which
point indomethacin was added and the solution vortexed
to stop synthesis [39]. After centrifugation, the superna-
tant was stored at –80C until duplicate analysis of PGE2
using an enzyme-linked immunosorbent assay (ELISA)
(R&D Systems, Minneapolis, MN, USA). To minimize
the interference of the Hank’s balanced salt solution with
the alkaline phosphatase enzyme (according to manufac-
turer’s specifications), standards were reconstituted us-
ing this solution as opposed to the buffer provided with
the kit. This kit does have cross-reactivity with PGE1
(70%) and PGE3 (16.3%). As prostanoid production of
the two series has previously been shown to be very
predominant in the kidney, even when diets are enriched
with other prostanoid series precursors [40], PGE2 would
represent the major molecule detected by a system that
recognizes both PGE1 and PGE2.
Statistical analysis
Results were analyzed using a general linear model
analysis of variance (ANOVA) with Tukey post hoc pair-
wise comparisons, using the Minitab version13 software
package (Minitab, Inc., State College, PA, USA). The
general linear model was used rather than a two-way
ANOVA because of the intrinsic unbalanced design that
arises from inability to predict the number of normal or
PKD animals in an experimental group at time of study
entry. The model detected differences between least
square means and detected interactions between diet and
disease, which were considered significant at P  0.05.
RESULTS
A total of 52 animals were studied, including 16 ani-
mals with normal kidneys, of which 8 received CLA diet
and 8 corn oil diet, and 36 PKD animals, of which 17
received CLA diet and 19 corn oil diet. PKD was associ-
ated with slightly reduced body weight (P  0.006) and
increased serum creatinine (P  0.003) (Table 2). Diet
did not influence body weight and changes in serum
creatinine did not reach significance (P  0.07). Creati-
nine clearance was significantly reduced by PKD (P 
0.002), but diet effects did not quite reach significance
(P  0.06) (Table 2). In post hoc testing, the creatinine
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Table 2. Animal weights and serum chemistry
Conjugated Conjugated
Corn oil linoleic acid Corn oil linoleic acid Diet effect Disease effect
Normal PKD P value
Animal weight g 369 (9.4) 372 (10.5) 351 (5.2) 350 (5.0) NS 0.006
Serum creatinine 	mol/L 80 (19) 77 (19) 132 (12)a 118 (12)a NS 0.003
Urine creatinine mmol/L 6.0 (0.45) 6.4 (0.42) 2.6 (0.30)a 4.1 (0.31)a,b 0.012 0.001
Urine volume mL/6 hours 2.57 (0.78) 2.88 (0.73) 6.54 (0.52) 5.73 (0.54) NS 0.001
Creatinine clearancea lL/min/100 g body weight 196 (31) 235 (31) 101 (20)a 162 (20) NS (0.06) 0.002
Serum cholesterol mmol/L 3.9 (1.3) 4.2 (1.6) 3.4 (0.8) 3.2 (0.6) NS NS
Serum triglyceride mmol/L 0.36 (0.09) 0.35 (0.06) 0.29 (0.05) 0.35 (0.05) NS NS
Figures are mean with SEM in parentheses.
a Polycystic kidney disease (PKD) animals significantly different from normal animals on same diet in post hoc comparisons, P  0.01
b Significantly different from control diet PKD animals in post hoc comparisons, P  0.004
Fig. 1. Morphometric assessment of cystic change in heterozygous
Han:SPRD-cy rats receiving corn oil (CO) or conjugated linoleic acid
(CLA) diets.
clearance difference between normal and PKD animals
was significant in animals on control diet (P  0.004),
but did not reach significance in animals receiving CLA
(P  0.15). As the brevity of the urine collection would
increase inaccuracies due to missed voids, urine volume
and urine creatinine were analyzed separately. Urine
volume was significantly increased in the presence of
PKD (P  0.001), but was not influenced by diet. Urine
creatinine concentration, however, was both significantly
reduced by the presence of PKD (P  0.01), and raised
by CLA feeding in PKD animals (dietary effect P 
0.012, post hoc comparison to PKD animals on control
diet, P  0.004) (Table 2). Serum cholesterol and total
triglyceride were not influenced by either disease status
or dietary intervention (Table 2).
CLA feeding did not influence cystic change (Fig. 1).
Renal fibrosis (P  0.03) (Fig. 2) and macrophage infil-
tration (P  0.001) (Fig. 3) were, however, significantly
reduced. Although scoring for ox-LDL staining (Fig. 4)
was somewhat lower in the CLA group, this difference
did not quite reach statistical significance (P  0.07).
CLA significantly reduced renal prostaglandin release
(P  0.022) (Fig. 5) in both healthy and PKD animals.
Analysis of fatty acid proportions in kidney demon-
Fig. 2. Morphometric assessment of interstitial fibrosis in heterozygous
Han:SPRD-cy rats receiving corn oil (CO) or conjugated linoleic acid
(CLA) diets.
Fig. 3. Morphometric assessment of macrophage infiltration as a mea-
sure of inflammation in heterozygous Han:SPRD-cy rats receiving corn
oil (CO) or conjugated linoleic acid (CLA) diets.
strated significant accumulation of CLA isomers in renal
tissue (P  0.001). The only CLA dietary effects noted
were a slight elevation of PT (P  0.03) despite lower
dietary content and decline in PO (P  0.04), with a
corresponding significant increase in PT/PO ratio (P 
0.04), and a reduction in OL (P  0.015) and increase
in ST:OL ratio (diet effect, P  0.038; disease effect,
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Fig. 4. Morphometric assessment of oxidized low-density lipoprotein
(ox-LDL) staining in heterozygous Han:SPRD-cy rats receiving corn
oil (CO) or conjugated linoleic acid (CLA) diets.
0.006), consistent with decreased -9 desaturase activity
(Table 3).
Analysis of hepatic fatty acid proportion also con-
firmed accumulation of CLA isomers (P  0.001), but
in this tissue significant dietary and disease effects were
noted (Table 4). PT was reduced in the presence of PKD
(P 0.001), but PO was reduced by CLA in both normals
and rats with PKD (P  0.021). Although total 6:3
ratio was not altered significantly by disease or diet,
hepatic proportion of ALA and EPA was reduced by
CLA (P  0.001 and P  0.001, respectively) and DHA
was higher in diseased animals (P  0.015), but all of
these hepatic 3 PUFA were present only in very small
amounts in all groups. LA was reduced by diet (P 
0.001), consistent with the lower content due to substitu-
tion by CLA isomers. Despite this, AA was increased
by CLA (P  0.009) and the presence of PKD (P 
0.002) and the LA:AA ratio was reduced in CLA-fed
animals (P  0.001) actually suggesting enhanced con-
version of LA to AA. A significant interaction between
diet and disease (P 0.001) was only detected for hepatic
PT:PO ratio, due to a very large additive effect of CLA
to the increase in ratio seen in all PKD animals. Hepatic
ST proportions were increased significantly by CLA diet
(P  0.001) despite a lower ST content in the diet, and
by the presence of PKD (P 0.001). OL was reduced by
disease only (P 0.001), with a corresponding significant
increase in ST:OL ratio (diet effect, P  0.001; disease
effect, P  0.001). This is consistent with depression of
-9 desaturase activity by both diet and the presence of
renal disease.
DISCUSSION
Our results confirm that CLA is both significantly in-
corporated into renal tissue after dietary supplementa-
tion and is associated with significant biologic effects.
The antifibrotic and antiproliferative effects seen in dis-
eased kidneys were comparable to those seen due to
Fig. 5. Prostaglandin E2 (PGE2) production from renal tissue of healthy
() and Han:SPRD-cy rats () receiving corn oil or conjugated linoleic
acid (CLA) diets. PKD is polycystic disease. *Significantly different from
normal animals on same diet, P 0.014; overall dietary effect, P  0.022.
other effective dietary interventions that we have tried
[7, 8, 10]. The urinary creatinine findings suggest a func-
tional benefit that just failed to reach significance in
serum creatinine and creatinine clearance. In a relatively
large study of this kind, creatinine clearance is more
practical than inulin clearance, although less accurate.
It may, however, be confounded by inability to guarantee
that animals start and finish collections with an empty
bladder. Furthermore, CLA has been shown to increase
lean body mass in rodents, which might raise serum creat-
inine and exaggerate the effect of incomplete urine col-
lection [23].
The observed reductions in inflammatory and fibrotic
effects of the disease were the dominant histologic find-
ings in this time-limited study. The observation of a lesser
reduction in ox-LDL staining is an interesting finding.
It implies that the oxidant injury that has been well
described in this model [41] does not simply follow as a
consequence of inflammation. It would also seem likely
that CLA may be reducing inflammation through a
mechanism unrelated to lipid peroxidation.
Reduction in PGE2 and other inflammatory mediators
such as tumor necrosis factor- (TNF-), leukotriene
B4 (LKTB4), interleukin-1
 (IL-1
), and IL-6 has been
demonstrated in vitro in association with CLA exposure
[42]. Reduced PGE2 and other series 2 prostanoids, as
we have found in renal tissue in this experiment, have
been documented in vivo in female reproductive tract
[26] and bone [28]. Kelley et al [43], however, although
able to demonstrate incorporation of CLA isomers into
human peripheral blood mononuclear cells, were unable
to demonstrate any physiological effects with respect to
inflammatory mediators in circulating cells. It is unlikely
that the reduced PGE2 production that we have shown
is due to reduced availability of the precursor AA. In
renal tissue, there was no dietary effect on AA. We were
able, however, to demonstrate evidence of decreased -
9 desaturase activity as has been previously described in
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Table 3. Renal proportions of selected fatty acids
Conjugated Conjugated
Corn oil linoleic acid Corn oil linoleic acid Diet effect Disease effect
Normal PKD P value
16:0 PT 22.7 (1.1) 25.4 (1.7) 23.9 (0.5) 25.4 (0.7) 0.03 NS
16:1 PO 2.1 (0.7) 1.5 (0.4) 2.3 (0.3) 1.3 (0.2) 0.04 NS
18:0 ST 16.7 (2.0) 16.2 (1.8) 13.9 (0.9) 16.0 (1.1) NS NS
18:1 OL 14.3 (3.4) 11.8 (1.8) 18.2 (1.2) 12.9 (1.0) 0.015 NS
18:2 LA 15.7 (1.4) 17.2 (1.4) 19.0 (0.9) 17.5 (1.0) NS NS
18:2 CLA 0.09 (0.04) 0.67 (0.27) 0.07 (0.02) 0.92 (0.18) 0.001 NS
18:3 6 0.16 (0.05) 0.12 (0.05) 0.17 (0.03) 0.13 (0.03) NS NS
18:3 3 ALA 0.15 (0.04) 0.09 (0.02) 0.16 (0.03) 0.11 (0.03) NS NS
20:4 AA 22.2 (3.9) 21.9 (3.1) 15.9 (1.5) 19.4 (1.5) NS NS
20:5 EPA ND ND ND ND — —
22:6 3 DHA 0.46 (0.09) 0.42 (0.06) 0.25 (0.02) 0.30 (0.02) NS 0.001
6: 3 ratio 57.1 (2.0) 78.8 (10.8) 74.1 (7.5) 80.7 (7.4) NS NS
LA:AA ratio 1.18 (0.48) 1.06 (0.29) 1.54 (0.22) 1.12 (0.18) NS NS
PT:PO ratio 21.0 (5.7) 29.1 (8.1) 15.6 (2.6) 35.4 (6.6) 0.04 NS
ST:OL ratio 1.76 (0.44) 1.78 (0.40) 0.91 (0.13) 1.46 (0.19) 0.038 0.006
Abbreviations are: PKD, polycystic kidney disease; CLA, conjugated linoleic acid; PT, palmitic acid; PO, palmitoleic acid; ST, stearic acid; OL, oleic acid; LA,
linoleic acid; ALA, -linoleic acid; AA, arachidonic acid; EPA, eicopentaenoic acid; DHA, docosahexaenoic acid; ND, not detected; NS, not significant. Figures are
mean with SEM in parentheses. With the exception of ratio results, all results are expressed as a percentage of total lipids. 18:2 CLA is the sum of all detected
isomers of 18:2 other than 18:2 c9 c12.
Table 4. Hepatic proportions of selected fatty acids
Conjugated Conjugated
Corn oil linoleic acid Corn oil linoleic acid Diet effect Disease effect
Normal PKD P value
16:0 PT 21.3 (0.4) 22.6 (0.5) 20.2 (0.3) 20.1 (0.5) NS 0.001a
16:1 PO 2.1 (0.3) 1.4 (0.15) 1.5 (0.4) 0.5 (0.1) 0.021 NS
18:0 ST 11.1 (1.2) 15.1 (0.7) 14.6 (0.7) 18.7 (0.4) 0.001 0.001
18:1 OL 11.2 (1.3) 11.2 (0.6) 8.7 (0.6) 8.4 (0.3) NS 0.001
18:2 LA 24.7 (0.9) 21.6 (0.6) 24.6 (0.6) 22.7 (0.5) 0.001 NS
18:2 CLA 0.19 (0.12) 1.26 (0.09) 0.07 (0.01) 1.18 (0.05) 0.001 NS
18:3 6 0.32 (0.03) 0.22 (0.01) 0.42 (0.02) 0.24 (0.01) 0.001 0.005
18:3 3 ALA 0.37 (0.02) 0.25 (0.02) 0.30 (0.01) 0.22 (0.01) 0.001 0.002
20:4 AA 15.2 (1.4) 17.5 (0.8) 17.9 (0.7) 20.1 (0.5) 0.009 0.002
20:5 EPA 0.03 (0.004) 0.01 (0.004) 0.02 (0.003) 0.01 (0.003) 0.001 NS
22:6 3 DHA 0.89 (0.06) 0.99 (0.05) 1.04 (0.04) 1.09 (0.02) NS 0.015
6: 3 ratio 26.8 (1.9) 25.6 (0.8) 27.7 (0.8) 27.8 (0.8) NS NS
LA:AA ratio 1.77 (0.13) 1.26 (0.09) 1.43 (0.09) 1.14 (0.05) 0.001 NS
PT:PO ratio 12.3 (2.5) 18.1 (2.2) 19.9 (1.8) 42.1 (3.3) 0.001 0.001
ST:OL ratio 0.84 (0.19) 1.39 (0.14) 1.30 (0.11) 2.29 (0.13) 0.001 0.001
Abbreviations are: PKD, polycystic kidney disease; CLA, conjugated linoleic acid; PT, palmitic acid; PO, palmitoleic acid; ST, stearic acid; OL, oleic acid; LA,
linoleic acid; ALA, -linoleic acid; AA, arachidonic acid; EPA, eicopentaenoic acid; DHA, docosahexaenoic acid; NS, not significant. Figures are mean with SEM
in parentheses. With the exception of ratio results, all results are expressed as a percentage of total lipids. 18:2 CLA is the sum of all detected isomers of 18:2 other
than 18:2 c9 c12.
aSignificant interaction between diet and disease, P  0.001
CLA studies [20, 44], suggesting that the lack of effect
on AA was not due to a lack of physiologic effect due
to low dosing. Our in vivo results for hepatic tissue are
similar to the findings of Miller, Stanton, and Devery
[27], who noted increase AA uptake in response to CLA
and Bulgarella, Patton, and Bull [45] who noted AA
accumulation. Although we did not measure any eicosa-
noid products from liver, reduced metabolism of AA to
series 2 prostanoids as was demonstrated from renal
tissue might contribute to the accumulation of AA in
liver. The CLA diet was lower in ALA than the corn
oil diet but the dietary and hepatic tissue proportion
differences in ALA content were small compared to
the observed increase in AA content. As LA was also
reduced in the CLA diet, it seems unlikely that hepatic
AA proportion rose in CLA-fed animals due simply to
changes in relative abundance of ALA and LA in compe-
tition for -6 desaturase activity. The 6:3 ratio of the
CLA diet was higher than the control diet, although both
diets would be considered high 6:3 ratio diets. 6:3
ratio has been linked to changes in -6 desaturase activ-
ity, and subsequently AA, in some models [46], but ex-
trapolation from studies working at much lower ratios
is speculative. The proportions of all 3 PUFA, which
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may give rise to less inflammatory products and which
include the macrophage inhibitory DHA [47], were low
in both dietary groups but further reduced by dietary
CLA, eliminating the possibility that PGE2 production
was reduced due to an increase in competing 3 sub-
strates for cyclooxygenase (COX) activity. It is interest-
ing to note that, as seen in our previous studies, the
presence of even a mild uremic state is associated of
itself with significant changes in the hepatic proportions
saturated and PUFA [8, 10]. These changes are in the
direction of favoring the availability of local 6 sub-
strates for eicosanoid synthesis and may be a factor in
the accelerated inflammatory state that accompanies
worsening uremia.
If altered PUFA proportions are not responsible for
altered prostanoid synthesis, then altered activity of syn-
thetic enzymes is likely. The kidney expresses both COX-1,
COX-2 and specific prostaglandin synthases in a nephron
segment–specific fashion [48]. A direct effect of CLA on
these enzymes is a plausible hypothesis. We have re-
cently shown that PKD in the Han:SPRD-cy rat is associ-
ated with increased COX-1 and phospholipase A2 and
decreased COX-2 expression as measured by Western
blotting [49]. Diet induced changes in expression of these
enzymes, or their relationships to specific prostaglandin
synthases might explain our observations.
Unlike soy- and flax-based interventions [7, 8, 10], no
effect was observed on cyst formation, a possible index
for antiproliferative activity. This is somewhat surprising
given the wealth of literature on anticarcinogenic activity
of CLA [15, 16, 36, 42, 50, 51]. The majority of situations
in which CLA is protective involve chemically induced
carcinogenesis and modification of metabolism of carcin-
ogens may play a role. Yang, Glickman, and de Boer
[51] have also recently demonstrated that specific renal
responses to CLA treatment after exposure to the carcin-
ogen PhLP differ from other tissues in the body and are
gender-specific, with mutations prevented by CLA in
female animals, but not in males. The authors speculate
that hormonally induced differences in CLA metabo-
lism, possibly though cytochrome p450 pathways may be
responsible for the failure of CLA effect on proliferative
mutations. As all our animals in this study were male, a
similar phenomenon may be present and future studies
comparing gender responses are thus required. As loss
of heterozygosity through mutation has been proposed
as a mechanism specifically of the cystic component of
the pathology of PKD, the role of gender must be clearly
be considered in future studies of this agent [52].
Moya-Camarena and Belury [53] point out that even
among relatively closely related rodent species, signifi-
cant differences in CLA responses can be found. Modifi-
cation of chronic interstitial changes in the Han:SPRD-
cy rat suggests a possible useful role in the management
of progressive renal injury. Application to the therapeu-
tic human environment, however, will require further
research as to mechanism, longer-term studies on effects
on renal survival and other morbidity in disease models
and exploration of the role of specific isomers.
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